Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation.
Queralt Serra-CamprubíHelena VerdaguerWinona OliverosNúria Lupión-GarciaAlba Llop-GuevaraCristina MolinaMaria Vila-CasadesúsAnthony TurpinCindy NeuzilletJoan FrigolaJessica QuerolMariana Yáñez-BartoloméFlorian CastetCarles Fabregat-FrancoCarmen Escudero-IriarteMarta EscorihuelaEnrique J Arenas LahuertaCristina Bernadó Bernadó MoralesNoemí HaroFrancis J GilesOscar J PozoJosep M MiquelPaolo G NuciforoAna VivancosMarta MeléVioleta SerraJoaquín ArribasJosep TaberneroSandra PeiróTeresa MacarullaTian V TianPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our results suggest that advanced CCA patients with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1, are likely to benefit from PARPi therapy. This collection of CCA_PDXs provides new opportunities for evaluating drug response and prioritizing clinical trials.